Single cell sequencing unraveling genetic basis of severe COVID19 in obesity.
Beneficial inflammation
COVID-19
Deleterious inflammation
Immunologic switch
Obesity
Shared immunogenetics
Single cell sequencing
Journal
Obesity medicine
ISSN: 2451-8476
Titre abrégé: Obes Med
Pays: England
ID NLM: 101690300
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
14
08
2020
revised:
20
09
2020
accepted:
20
09
2020
pubmed:
1
10
2020
medline:
1
10
2020
entrez:
30
9
2020
Statut:
ppublish
Résumé
COVID-19 has shown a substantial variation in the rate and severity by which it impacts different demographic groups. Specifically, it has shown a predilection towards obese patients as well as well as other vulnerable groups including predilection of males over females, old age over young age and black races over Caucasian ones. Single cell sequencing studies have highlighted the role of cell polarity and the co-expression of proteases, such as Furin, along with ACE2 in the genesis of coronavirus disease rather than exclusively link tissue involvement with ACE2 levels thought previously. It has also forged a connection between the genetic and immune cellular mechanisms underlying COVID infection and the inflammatory state of obese patients, offering a more accurate explanation as to why obese patients are at increased risk of poor COVID outcomes. These commonalities encompass macrophage phenotype switching, genetic expression switching, and overexpression of the pro-inflammatory cytokines, depletion of the regulatory cytokines, in situ T cell proliferation, and T cell exhaustion. These findings demonstrate the necessity of single cell sequencing as a rapid means to identify and treat those who are most likely to need hospital admission and intensive care, in the hopes of precision medicine. Furthermore, this study underlines the use of immune modulators such as Leptin sensitizers, rather than immune suppressors as anti-inflammation therapies to switch the inflammatory response from a drastic immunological type 1 response to a beneficial type 2 effective one.
Identifiants
pubmed: 32995660
doi: 10.1016/j.obmed.2020.100303
pii: S2451-8476(20)30123-8
pmc: PMC7513689
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100303Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Authors declare that there is no conflict of interest.
Références
Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E984-90
pubmed: 14534074
Exp Mol Med. 2018 Aug 7;50(8):96
pubmed: 30089861
J Biomed Opt. 2015 Nov;20(11):115002
pubmed: 26538329
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
Front Physiol. 2020 Sep 18;11:555039
pubmed: 33071815
Obes Med. 2020 Sep;19:100281
pubmed: 32835124
Aging Cell. 2019 Jun;18(3):e12874
pubmed: 30821426
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Rev Immunol. 2014 Feb;14(2):81-93
pubmed: 24445666
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Clin Transl Immunology. 2019 Aug 05;8(8):e1073
pubmed: 31406574
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
Protein Cell. 2020 Oct;11(10):740-770
pubmed: 32780218
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Clin Rev Allergy Immunol. 2019 Jun;56(3):308-321
pubmed: 28963611
Molecules. 2020 Apr 29;25(9):
pubmed: 32365556
Curr Immunol Rev. 2008 May 1;4(2):70-79
pubmed: 20198122
Cancer Lett. 2020 Nov 1;492:44-53
pubmed: 32738272
BMJ Open. 2020 Aug 11;10(8):e039849
pubmed: 32784264
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Clin Exp Otorhinolaryngol. 2020 May;13(2):83-84
pubmed: 32434304
Sci Rep. 2019 Aug 22;9(1):12284
pubmed: 31439906
J Pathol. 2008 Dec;216(4):387-93
pubmed: 18853439
Front Immunol. 2016 Jan 05;6:637
pubmed: 26779183
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
Front Immunol. 2018 Sep 07;9:1930
pubmed: 30245686
Lancet Respir Med. 2020 Aug;8(8):750-752
pubmed: 32422177
Oncotarget. 2018 Apr 3;9(25):17443-17454
pubmed: 29707119
Science. 2017 May 26;356(6340):
pubmed: 28495876
J Obes. 2020 Jan 30;2020:5076858
pubmed: 32089876
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Am J Physiol Endocrinol Metab. 2013 Mar 1;304(5):E466-77
pubmed: 23269411
PLoS One. 2012;7(11):e48605
pubmed: 23139800
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423094
Protein Sci. 2018 Jan;27(1):233-244
pubmed: 28940711
Cell Rep. 2019 Apr 9;27(2):514-524.e5
pubmed: 30970254
Emerg Microbes Infect. 2020 Dec;9(1):1474-1488
pubmed: 32543348
Rev Endocr Metab Disord. 2015 Mar;16(1):47-54
pubmed: 25526866
Med Hypotheses. 2020 Nov;144:110053
pubmed: 32758889
J Immunol. 2009 Oct 1;183(7):4177-81
pubmed: 19767567
Gastroenterology. 2020 May;158(6):1518-1519
pubmed: 32142785
J Virol. 2011 Jan;85(2):873-82
pubmed: 21068237
Mol Metab. 2016 Sep 13;5(11):1131-1137
pubmed: 27818939
Int J Obes (Lond). 2016 May;40(5):844-51
pubmed: 26620890
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Front Immunol. 2018 Mar 21;9:552
pubmed: 29619026
Nat Rev Drug Discov. 2016 Sep;15(9):601
pubmed: 27539125
Appl Biochem Biotechnol. 2019 May;188(1):241-259
pubmed: 30417321
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
J Clin Invest. 2006 Jan;116(1):115-24
pubmed: 16341265
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
J Pathol. 2020 Jul;251(3):228-248
pubmed: 32418199
JAMA Netw Open. 2020 Aug 3;3(8):e2018696
pubmed: 32809027